Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 14

Drug Profile

IC 14

Alternative Names: Anti-CD14 antibody

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ICOS Corporation
  • Developer ICOS Corporation; Implicit Bioscience; University of Washington
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action CD14 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury
  • Phase I Motor neuron disease
  • Clinical Phase Unknown Adult respiratory distress syndrome
  • Discontinued Septic shock

Most Recent Events

  • 25 Sep 2019 Implicit Bioscience plans the HEALEY ALS Platform clinical trial for Amyotrophic lateral sclerosis in USA
  • 14 Mar 2019 Implicit Bioscience withdraws a phase II trial prior to enrolment for Dengue fever due to issues in seeking funding (NCT03875560)
  • 14 Mar 2019 Implicit Bioscience withdraws prior to enrolment a phase II trial for Acute respiratory distress syndrome in USA, as the company seeks funding (NCT03017547)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top